On November 15, Pfizer’s adalimumab product became the 25th biosimilar approved by FDA under the Biologics Price Competition and Innovation Act (BPCIA). The road to the 25th approval has been long and has involved some of the biggest companies and medications in the pharmaceutical industry. In this post, we take a brief look at how we got here, where things stand for the 25 approved biosimilars, and where we are headed next.
Because No One is Immune to the Law